EFNA3 and gastric cancer: The results of GEPIA2 analysis showed that high expression of EFNA3 was associated with longer OS (HR = 0.63, p = 0.0038) and DFS (HR = 0.67, p = 0.04) of GC patients (Figures 2A,B) compared with GC patients with low EFNA3 expression.